Q&A: Bring your own device: How patients own tech is being used in clinical trials

Vivalink has developed an application to allow patients to use their own devices for remote monitoring in clinical trials. Credit: Shutterstock / Andrey_Popov

Keeping track of your pulse, heart rate and oxygen saturation has never been easier, with smartwatches able to easily track a large amount of health data. In addition, most people use a smartphone daily and users can track their steps and monitor their calorie intake. 

Technology has advanced over the past decade, and patients can record, monitor and store a great deal of data about their health on their smart devices. 

With concerns about the growing amount of e-waste, could utilising patients’ own devices alongside reusable medical-grade monitoring devices be the answer to reducing e-waste in remote monitoring of patients during clinical trials?

A report by GlobalData found that Remote Patient Monitoring (RPM) devices are expected to be worth $760m by 2030. GlobalData is the parent company of the Clinical Trials Arena. 

Clinical Trials Arena sat down with Vivalink vice president Sam Liu to discuss how technology has advanced so that patients are able to use their own devices for remote monitoring in clinical trials. 

Sam Liu: ​​​​​​​The main thing is familiarity as patients are already using that device as part of their lifestyle. The number one challenge with remote patient monitoring in any setting is getting the patients to use the device correctly. When it’s your own device, you’re very familiar with it and you already have a daily routine based on it, so that’s probably the main advantage. There is also the benefit of it being a reusable device which reduces the need for extra components, or wasteful components. 

I also think the mentality of using your own devices for healthcare has changed over time, whether it’s an app on a smartphone or a wearable, they are used commonly to track the user’s health. We are now seeing this in unwell patients, with a switch from conventional methods such as hospital monitoring before the pandemic to more telehealth based care. That infrastructure depends on access to devices and if consumers already have these, that’s even better. 

Sam Liu: There are several challenges with the bring-your-own-device model. First is that there are so many variations on devices – even with Apple devices, there are different versions of operating systems and different versions of hardware. If you’re looking at Android, it goes beyond that in terms of variation. This can become a problem with the technology because you need to ensure compatibility. Another challenge is that with patients using their own devices, there could be issues with security if unknown parties have the ability to access that personal health information.

Sam Liu: This depends on what the application is because there’s a difference between the actual medical wearables and a consumer device that may be used to supplement that. In some trials we are involved with, we provide medical wearables, such as an ECG. Patients can then use an app on a device like a smartphone that connects to the device and also collects simple patient survey data and patient-reported symptoms. In some circumstances, patients may be able to get enough data from their own wearables if they have them. It really depends on what the sponsor needs.

Sam Liu: That’s part of the implementation and planning by the company providing the technology. In our company for example, we work with the sponsors and sites to plan out the data workflow; how the data should be collected, where’s it going, and what it’s being used for. That understanding of the data is important and at that point, the processing and security can be considered. In our system, we try to avoid identifying patients along the data chain as much as possible, patients will be a unique identifier, a string of numbers and letters. When it gets to the site or sponsor, they can work out which patient it relates to using the identifier.

Sam Liu: ​​​​​​​The value proposition is different depending on the study but overall, I think what sponsors like is the fact that they can get access to a richer set of data that will improve their R&D process, whether it’s at the early phase stages or later phase stages. It is important for sponsors to be comfortable implementing something like this as part of their protocols and trials. We basically abstract the technology for the sponsor so from their perspective, they just get a data service from us while we worry about all the nuances and logistics of it working correctly. 

One concern from sponsors is what they do with all the data because it is almost too much data. The sensors generate data, but that doesn’t mean it all needs to get processed. In the workflow design, you decide what type of data you’re trying to capture. I also think AI can help here with its ability to process larger amounts of data. 

Sam Liu: The patient reported symptoms are growing in trials and healthcare but it is either sometimes not timely, or not accurate. By adding in sensors, you have quantified data which can correlate with patient-reported symptoms to support some of those reports. As a result, I think they will be used more and more in time.